BioArctic Recognized for Sustainable Innovation in Nasdaq Stockholm’s ESG Responsibility Index

228

BioArctic’s steadfast commitment to sustainable innovation has earned the company a coveted spot in the new OMX Sweden Small Cap 30 ESG Responsibility Index . This index showcases companies leading the way in environmental, social, and corporate governance (ESG) practices within the Swedish market.

Charlotte af Klercker, Corporate Sustainability Director at BioArctic, expressed pride in the company’s inclusion in the Small Cap 30 ESG Responsibility Index, emphasizing its dedication to integrating sustainability across all facets of its operations. BioArctic’s focus on developing safe and effective drugs for neurodegenerative diseases underscores its commitment to making a positive impact on patients, their families, and society.

BioArctic’s approach to sustainable innovation extends beyond research and development to encompass responsible business practices and environmental stewardship. Through continuous improvement of procedures and quality management systems, the company strives to uphold prevailing legislation and minimize its environmental footprint.

As a leader in sustainable innovation, BioArctic is honored to be recognized in Nasdaq Stockholm’s ESG Responsibility Index, reaffirming its position as a responsible corporate citizen driving positive change in the healthcare industry and beyond.